Most frequent aberrations in ACC
| Cytoband | Size of region (Mbps) | No. tumors, n (%) | Candidate genes | ||
|---|---|---|---|---|---|
| Gains | 1p36.33-p35.3 | 27.70 | 8 (44) | E2F2, TNFRSF4 | |
| 1p35.2-p33 | 16.11 | 8 (44) | CSF3R, PTPRF, HDAC1 | ||
| 2q37.3 | 0.58 | 5 (28) | — | ||
| 4p16.3 | 1.69 | 5 (28) | FGFR3, CTBP1 | ||
| 5q32-q33.1 | 3.67 | 7 (39) | PDGFRB | ||
| 8q24.3 | 3.80 | 7 (39) | PLEC1 | ||
| 9q33.3-q34.3 | 11.44 | 13 (72) | ABL1, NOTCH1, TRAF2 | ||
| 11p15.5 | 1.82 | 6 (33) | MUC2, HRAS | ||
| 11q13.3 | 0.37 | 11 (61) | FGF3, FGF4, FGF19 | ||
| 11q23.3 | 2.30 | 11 (61) | IL10RA, MLL, CBL | ||
| 12q13.2-q14.1 | 1.77 | 5 (28) | ERBB3, STAT6, RAB5B, WNT1 | ||
| 13q34 | 1.04 | 6 (33) | TFDP1, GAS6 | ||
| 16p13.3 | 4.42 | 8 (44) | MMP25, SOX8, RAB26 | ||
| 16q24.3 | 0.05 | 7 (39) | — | ||
| 17p13.3 | 1.84 | 7 (39) | CRK | ||
| 17q11.2-q25.3 | 55.15 | 5 (28) | ERBB2, PPMD1, ITGB4 | ||
| 19p13.3-p13.11 | 17.90 | 14 (78) | RAB8A, FGF22, ICAM5 | ||
| 19q12-q13.43 | 26.75 | 14 (78) | TGFB1, BCL3 | ||
| 20q13.33 | 2.64 | 5 (28) | SOX18, PTK6, RTEL1, TNFRSF6B | ||
| 21q22.3 | 3.21 | 11 (61) | ITGB2, PTTG1IP, COL18A1, S100B | ||
| 22q13.33 | 1.21 | 13 (72) | ECGF1, MAPK12 | ||
| Losses | 1p21.3-p12 | 23.73 | 2 (11) | ST7L | |
| 5q21.1 | 2.49 | 3 (17) | ST8SIA4 | ||
| 5q21.3-q23.2 | 18.82 | 3 (17) | APC | ||
| 9p22.3-p13.3 | 20.47 | 3 (17) | CDKN2A | ||
| 12q12-q14.1 | 23.01 | 2 (11) | KRT7, HOXC5 | ||
| 13q14.3-q21.32 | 13.22 | 2 (11) | PCDH17, PCDH9, INTS6 | ||
| 14q11.2-q31.3 | 64.52 | 4 (22) | SEL1, DLG7, NFKBIA | ||
| 17p13.1-q11.1 | 12.93 | 2 (11) | LLGL1 | ||
| 20q11.23-q12 | 1.98 | 3 (17) | DHX35 | ||
NOTE: Most frequently gained (>25%) and lost (>10%) minimal common regions of overlap were detected by array CGH in 18 primary ACCs, together with candidate oncogenes and tumor suppressor genes. The size of the aberration is depicted in mega-bps (Mbps).